A private equity investor, Advent, has announced that the amount managed by it has signed a certain agreement to invest $ 175 million through primary and secondary capital for an important minority stake in Felix Pharmaceuticals Private, Dublin, Ireland. Ltd. (Felix), a global GX Animal Pharma Player.
Felix Pharma is one of the developers and manufacturer of off-pattant drugs for fellow animals.
Felix develops, manufactures and supplies distributors and other branded GX players for private labeling, especially in America
Advent’s managing partner, Shweta Jalan said, “Healthcare has been focused on a long time for us, and strong similarities we see in animal health GX amidst success in human GX in human GX. Felix has been well deployed to lead this place with its strong leadership, comprehensive portfolio and strong river and d and commercial abilities.
He said, “Its rapid development and high customer satisfaction makes it a differential platform, and we are excited to support Neeraj and Felix team to score to a global franchise,” she said, “
In 2015, Neeraj Agwal, a McInsey alum, Sir Jonathan Symonds, GSK President and Global Pharmaceuticals with 30 years of experience, and the Bose-Elon’s ex-CEO, Felix’s ex-CEO, Felix said that it was a disciplined approach to strategic development through a disciplined approach.
While the company achieved its first US FDA approval in 2020, it quickly scored 14 business products portfolio and many others in advanced stages of the pipeline.
It has a USFDA-approved oral solid facility dedicated to animal health products and is expected to be prepared by Q3 2025.
Felix Pharma co-founder Neeraj Aggarwal said, “As we are on a scale in a rapidly developed market, we were looking for a partner who not only brings capital, but also to help deep operating expertise and correct mindset and network to grow faster.
Published – June 09, 2025 11:23 pm IST
